Substrate-specific pharmacokinetic interaction between endothelin receptor antagonists and phosphodiesterase-5 inhibitors - Assembling the clues

British Journal of Clinical Pharmacology

Volumn 67, Issue 4, 2009, Pages 475-477

  Srinivas, Nuggehally R ^a  

^a Integrated Drug Development   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL;

DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG CROSS REACTIVITY; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG INHIBITION; DRUG LIVER LEVEL; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; HUMAN; INHIBITION KINETICS; LETTER; LIVER METABOLISM; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SINGLE DRUG DOSE;

ANTIHYPERTENSIVE AGENTS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DRUG INTERACTIONS; HUMANS; PHOSPHODIESTERASE INHIBITORS; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 63849300375     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03374.x     Document Type: Letter

References (25)

1. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ, Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002 165 : 800 4.
2. Gabbay E, Fraser J, McNeil K. Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag 2007 3 : 887 900.
3. Duuis J, Harper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008 31 : 407 15.
4. Wilkins MR, Wharton J, Grimminger F, Ghofrani HA. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 2008 32 : 198 209.
5. Croom KF, Curran MP, Abman SH, Channick RN, Heresi GA, Rubin LJ, Torbicki A. Sildenafil: a review of use in pulmonary arterial hypertension. Drugs 2008 68 : 383 97.
6. Kamata Y, Iwamoto M, Minota S. Consecutive use of sildenafil and bosentan for the treatment of pulmonary arterial hypertension associated with collagen vascular disease : sildenafil as reliever and bosentan as controller. Lupus 2007 16 : 901 3.
7. Cheng JW. Ambrisentan for the management of pulmonary arterial hypertension. Clin Ther 2008 30 : 825 33.
8. Lunze K, Gilbert N, Mebus S, Miera O, Fehske W, Uhlemann F, Mühler EG, Ewert P, Lange PE, Berger F, Schulze-Neick I. First experience with oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. Eur J Clin Invest 2006 36 (Suppl. 3 32 8.
9. Minai OA, Arroliga AC. Long-term results after addition of sildenafil in idiopathic PAH patients on bosentan. South Med J 2006 99 : 880 3.
10. Mogollon MV, Lage E, Cabezon S, Hinojosa R, Ballesteros S, Aranda A, Sobrino JM, Ordóñez A. Combination therapy with sildenafil and bosentan reverts severe pulmonary hypertension and allows heart transplantation: case report. Transplant Proc 2006 38 : 2522 3.
11. Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokin 2004 43 : 1089 115.
12. Muirhead GJ, Rance DJ, Walker DK, Wastall P. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. Br J Clin Pharmacol 2002 53 (Suppl. 1 13S 20S.
13. Warrington JS, Shader RI, von Moltke LL, Greenblatt DJ. In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos 2000 28 : 392 7.
14. Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, Wright PA. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999 29 : 297 310.
15. Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 2005 45 : 987 1003.
16. Lilly and Co. CIALIS™. Available at http://pi.lilly.com/us/cialis- pi.pdf (last accessed 18 February 2009).
17. Ring BJ, Patterson BE, Mitchell MI, Vandenbranden M, Gillespie J, Bedding AW, Jewell H, Payne CD, Forgue ST, Eckstein J, Wrighton SA, Phillips DL. Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo. Clin Pharmacol Ther 2005 77 : 63 75.
18. Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, Mitchell MI. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2006 61 : 280 8.
19. Burgess G, Hoogkamer H, Collings L, Dingermanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008 64 : 43 50.
20. Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005 60 : 107 12.
21. Bachmann K, Ghosh R. The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions. Curr Drug Metab 2001 2 : 299 314.
22. Treiber A, Schneiter R, Hausler S, Stieger B. Bosentan is a substrate of human oatp1b1 and oatp1b3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporine a, rifampicin and sildenafil. Drug Metab Dispo 2007 35 : 1400 7.
23. Wrishko RE, Dingermanse J, Yu A, Darstein C, Phillips DL, Mitchell MI. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol 2008 48 : 610 8.
24. Barst RJ. A review of pulmonary arterial hypertension: role of ambrisentan. Vasc Health Risk Manag 2007 3 : 11 22.
25. Gilead Co. LETAIRIS™. Available at http://www.gilead.com/pdf/ letairis-pi.pdf (last accessed 18 February 2009).